Attend the 15-minute Ask the Expert Webcast on November 14, 2024
Evaluation of a New Multimodal Anion Exchange Resin for Emerging Biotherapeutic Process Challenges
Join Michael Rauscher, Associate Principal Scientist, Process R&D Enabling Technologies at Merck & Co., Inc., for our 15‑minute Ask the Expert Webcast
In this webcast, Michael will present high‑throughput resin screening data of an IgG1 monoclonal antibody (mAb), an IgG4 mAb, and a bispecific antibody (bsAb) for downstream process development utilizing Bio‑Rad's new Nuvia wPrime 2A Resin. Optimization included modulating the charge state of the resin. The resin offered a wide design space for the studies and resulted in increased yields and reductions of aggregates and host cell proteins (HCPs).
Key Takeaways:
- The ability to modulate the resin's charge state provided a wide‑design space
- Screening results showed improved yields and reductions in impurities compared to traditional strong ion exchange and strong AEX‑HIC resins